New research finds that measuring blood levels of the medication hydroxychloroquine (Plaquenil) in people with lupus may be an effective way to predict risk of retinopathy, a disease which results in impaired or complete loss of vision.
A new study shows that pregnancy and breastfeeding could change the way the body reacts to conventional lupus treatment in women due to imbalances in the gut bacterial community, or dysbiosis. The research was undertaken to understand the higher risk of severe flares and help women with lupus experience healthy pregnancies and successful outcomes, by improving therapeutic approaches.
A new study published in the journal Arthritis & Rheumatology finds there may be a genetic explanation for the development of systemic lupus erythematosus (SLE) in African American women.
The study, published on August 20, points to epigenetic changes near interferon-regulated genes early in B cell development. These changes are a “hallmark” of SLE development in African American women, the authors wrote.
“We have identified an aberrant epigenetic signature that developed early in B cell development in African American patients. This observation is consistent with recently published work which identified a SLE-specific epigenetic signature present in the resting naïve B cell stage that persists throughout development in a cohort of Africa American females,” wrote the authors who were led by Devin Absher, Ph.D., of the HudsonAlpha Institute for Biotechnology in Alabama.
Oklahoma Medical Research Foundation (OMRF) scientists have discovered that the Epstein-Barr virus may be a possible trigger for the development of lupus in at-risk individuals.
Scientists have long known lupus has a strong genetic component, but there also must be environmental triggers to activate the disease.
Autoantibodies targeting certain regulatory RNAs — molecules that serve as the template for protein production — in the brains of lupus patients are unique to these people and involved in neuropsychiatric symptoms of the disease, a study reports.
The study, “Neuronal BC RNA transport impairments caused by systemic lupus erythematosus autoantibodies,” was published in the Journal of Neuroscience.
In a new study, researchers looked at whether treatments targeting B-cell activating factor (BAFF) have an impact on human B-cells, as previous studies have suggested. B-cells are responsible for creating antibodies, including autoantibodies, and are thought to play a role in the development and progression of autoimmune diseases.
A breakthrough study by a SUNY Downstate Health Sciences University research team has identified a specific antibody target implicated in neuropsychiatric symptoms of lupus. These symptoms, including cognitive impairment, mood disorders, seizures, headaches and psychosis, are among the most prevalent manifestations of the disease and occur in as many as 80% of adults and 95% of children with lupus.
Researchers have discovered that blood clotting proteins in urine can act as biomarkers in patients with systemic lupus erythematosus (SLE), especially those with lupus nephritis.
The team of researchers at the University of Houston found that blood clotting proteins, both the ones that promote blood clotting (prothrombic) and those that disperse them (thrombolytic) are elevated in the urine of patients with lupus nephritis (LN).
Individuals with systemic lupus erythematosus (SLE) who have primary total hip arthroplasty (THA) are at higher risk for implant infection, discharge to an inpatient facility, more expensive hospital bills, and increased blood transfusions than people without SLE, according to a study recently published in Lupus.
In a study published in a recent issue of Arthritis & Rheumatology, investigators found that patients with lupus nephritis were far more likely to break a bone than patients who do not have lupus.
“Patients with lupus nephritis may be at particularly high risk of fracture due to secondary or tertiary hyperparathyroidism and vitamin D deficiency,” said study author Sara Tedeschi, M.D., MPH, a rheumatology fellow at Brigham and Women’s Hospital.
The Lupus Research Alliance shared positive topline results from a Phase 2 clinical study of a potential new treatment for proliferative lupus nephritis, the most severe form of kidney damage caused by lupus. Genentech, a member of the Roche Group, reported that at one year their drug Gazyva® (obinutuzumab) helped more patients achieve a complete response to treatment when added to standard of care with either mycophenolate mofetil or mycophenolic acid plus corticosteroids than those receiving standard of care alone.
Hydroxychloroquine (Plaquenil®) is the most prescribed medication in the treatment of lupus and has numerous benefits including prevention of flares, prolonged survival, and other positive outcomes. Medication non-adherence is reported in up to 80% of people with lupus and is associated with reduced health outcomes.
People with lupus produce autoantibodies causing the body to attack itself and promoting inflammation and tissue damage. A new research study divided people with lupus into two cohorts, or groups, so they could identify key differences. One group consisted of first-degree relatives (FDRs) without lupus and healthy people, and their molecular profiles were compared against a second group, which consisted of unrelated people with and without lupus.
The kidneys of patients living with systemic lupus erythematosus (SLE) are often under assault, and not all those living with the disease will respond to standard treatment. A new report published in the journal Nature Immunology online May 20 shows how tissue samples from these patients can accurately predict those more likely than not to respond to therapy. SLE is a disease marked by the attack on joints, skin, and kidneys by the body's immune system..
Osteopontin (OPN) is a protein present in the bone and other tissues. Elevated levels of OPN have been observed in several autoimmune diseases including lupus. Investigators from a group called Systemic Lupus International Collaborating Clinics (SLICC) examined data from 344 people with lupus over the course of five years to determine whether raised OPN is a reliable biomarker for lupus. Specifically, they wanted to know if increased levels of OPN could predict damage; reflect current disease activity; or if increased OPN levels are associated with certain disease phenotypes (characteristics).